 PASADENA, CA, Oct. 13, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings , Inc. Nasdaq: LIXT announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam NKI , one of the worlds leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations. 